Despite the strong structural similarity (85% homology) between CYP3A4 and CYP3A5, CYP3A5 polymorphisms had no association with overall survival, patient outcomes, or chemotherapy toxicity in ovarian cancer patients treated with platinum and taxane drugs [51,94,105]. The gene discussed is CYP3A5; the disease is ovarian carcinoma.